Evidence map›Paper›PMID 36517458›Full record

ArticleCancer reports (Hoboken, N.J.)2023

FIP1L1-PDGFRA fusion gene in T-lymphoblastic lymphoma: A case report.

Salhah Ali, Yasmine Al-Qattan, Walaa Awny, Abdulaziz Hamadah, Karen Pinto, Salem AlShemmari

Open access · goldAbstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancer reports (Hoboken, N.J.), 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.2field-weighted citation impact, top 44% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 2 citations in OpenAlex.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 1 country.

Salhah AliDepartment of Hematology, Mubarak Al-Kabeer Hospital, Jabriya, Kuwait.
Yasmine Al-QattanDepartment of Hematology, Mubarak Al-Kabeer Hospital, Jabriya, Kuwait.
Walaa AwnyDepartment of Hematopathology, Kuwait Cancer Control Center, Kuwait, Kuwait.
Abdulaziz HamadahDepartment of Hematology, Kuwait Cancer Control Center, Kuwait, Kuwait.
Karen PintoDepartment of Pathology, Kuwait Cancer Center, Kuwait, Kuwait.
Salem AlShemmariDepartment of Hematology, Kuwait Cancer Control Center, Kuwait, Kuwait.ORCID 0000-0002-5597-5839
Kuwait Cancer Control Center · KWMubarak Al Kabeer Hospital · KW

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundT-lymphoblastic lymphoma (T-LBL) is an aggressive malignancy of T-lymphoid precursors, rarely co-occurring with myeloid/lymphoid neoplasms with eosinophilia (M/LNs-Eo), with consequent rearrangement of tyrosine kinase (TK)-related genes. The FIP1L1-PDGFRA fusion gene is the most frequent molecular abnormality seen in eosinophilia-associated myeloproliferative disorders, but is also present in acute myeloid leukemia (AML), T-lymphoblastic leukemia/lymphoma (TLL), or both simultaneously. T-LBL mainly affects children and young adults, involving lymph node, bone marrow, and thymus. It represents about 85% of all immature lymphoblastic lymphomas, whereas immature B-cell lymphomas comprise approximately 15% of all cases of LBL. CASE: In this case report, we present an example of T cell lymphoblastic lymphoma with coexistent eosinophelia, treated successfully with a tyrosine-kinase inhibitor (TKI).

conclusionFIP1L1-PDGFRA-positive T-LBL and myeloproliferative disorders have excellent response to low-dose treatment with (TKI) imatinib. Most patients achieve rapid and complete hematologic and molecular remission within weeks.

Indexed as

EosinophiliaMyeloproliferative DisordersPrecursor Cell Lymphoblastic Leukemia-LymphomaPrecursor T-Cell Lymphoblastic Leukemia-LymphomaChildHumansImatinib MesylatemRNA Cleavage and Polyadenylation FactorsOncogene Proteins, FusionProtein Kinase InhibitorsReceptor, Platelet-Derived Growth Factor alphaFIP1L1-PDGFRA fusion protein, humanImatinib MesylatemRNA Cleavage and Polyadenylation FactorsOncogene Proteins, FusionProtein Kinase InhibitorsReceptor, Platelet-Derived Growth Factor alphaeosinophiliaFIP1L1-PDGFRATLLT lymphoblastic lymphoma

Identifiers

PMID36517458
PMCPMC9875631
OpenAlexW4311468385

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.